Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Valero Energy Corporation — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Valero Energy Corporation trades at $461.26 (market cap $131.43B). The key difference: Valero Energy Corporation is far larger — about 26.9× Travere Therapeutics Inc. Common Stock's market cap, and Valero Energy Corporation pays a 1.05% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Valero Energy Corporation for 57 Days on average.
| TVTX | VLO | |
|---|---|---|
Market Cap | $4.88B | $131.43B |
Volume | 1,668,577 | 2,513,030 |
Sector | Health | Energy |
52-Week High | $67.52 | $459.78 |
52-Week Low | $26.79 | $156.39 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $5.01B | $134.90B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Valero Energy (VLO) trades at $459.78, up 5.45% today, near its 52-week high. The stock exhibits strong bullish momentum with recent earnings beats and positive technical signals. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a 56.76% buy rating, though the current price exceeds the $408.10 consensus target. Recent news highlights institutional inflows and refining margin strength.
Outlook is positive due to earnings momentum and favorable sector trends, but risks include potential policy impacts on diesel exports and high valuation multiples. The stock's proximity to resistance at $460 suggests near-term consolidation may occur. Long-term growth depends on sustaining refining margins and cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
